CAUTIONARY NOTE ON FORWARD-LOOKING STATEMENTS

Certain statements in this presentation regarding strategic plans, expectations and objectives for future operations or results are “forward-looking statements” as defined by the Private Securities Litigation Reform Act of 1995. These statements may be identified by the use of forward-looking words such as “anticipate,” “believe,” “forecast,” “estimate” and “intend,” among others. These forward-looking statements are based on Tonix’s current expectations and actual results could differ materially. There are a number of factors that could cause actual events to differ materially from those indicated by such forward-looking statements. These factors include, but are not limited to, the risks related to failure to obtain FDA clearances or approvals and noncompliance with FDA regulations; delays and uncertainties caused by the global COVID-19 pandemic; risks related to the timing and progress of clinical development of our product candidates; our need for additional financing; uncertainties of patent protection and litigation; uncertainties of government or third party payor reimbursement; limited research and development efforts and dependence upon third parties; and substantial competition. As with any pharmaceutical under development, there are significant risks in the development, regulatory approval and commercialization of new products. The forward-looking statements in this presentation are made as of the date of this presentation, even if subsequently made available by Tonix on its website or otherwise. Tonix does not undertake an obligation to update or revise any forward-looking statement, except as required by law. Investors should read the risk factors set forth in the Annual Report on Form 10-K for the year ended December 31, 2020, as filed with the Securities and Exchange Commission (the “SEC”) on March 15, 2021, and periodic reports and current reports filed with the SEC on or after the date thereof. All of Tonix’s forward-looking statements are expressly qualified by all such risk factors and other cautionary statements.
WHAT WE DO

OUR MISSION
ADVANCING THE SCIENCE AND UNDERSTANDING OF DISEASES by developing innovative therapies that improve population health by focusing on unmet needs in patient care

OUR STRATEGY
Using our integrated development engine, we advance innovative programs across multiple therapeutic areas into the clinic while maximizing asset potential
## PIPELINE

### INFECTIOUS DISEASE & IMMUNOLOGY PORTFOLIO

<table>
<thead>
<tr>
<th>CANDIDATES</th>
<th>PORTFOLIO &amp; INDICATION</th>
<th>STATUS / NEXT MILESTONE</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>COVID</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>TNX-1800¹</td>
<td>COVID-19 Vaccine</td>
<td>Phase 1, Targeting 2H 2022 Start</td>
</tr>
<tr>
<td>TNX-102 SL²</td>
<td>Long COVID-19 (Post-Acute Sequelae of COVID-19 or PASC)</td>
<td>Phase 2, Targeting 1H 2022 Start</td>
</tr>
<tr>
<td>TNX-2100³</td>
<td>SARS-CoV-2 Diagnostic for T Cell Immunity</td>
<td>First-in-human study, Initiated Q1 2022</td>
</tr>
<tr>
<td>TNX-3500⁴</td>
<td>COVID-19 Antiviral</td>
<td>Preclinical</td>
</tr>
<tr>
<td>TNX-3600⁵</td>
<td>COVID-19 Therapeutic Platform (monoclonal antibodies)</td>
<td>Preclinical</td>
</tr>
<tr>
<td>TNX-3700⁶</td>
<td>COVID-19 Vaccine</td>
<td>Preclinical</td>
</tr>
<tr>
<td><strong>BioDefense</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>TNX-801⁷</td>
<td>Smallpox and monkeypox preventing vaccine</td>
<td>Preclinical</td>
</tr>
<tr>
<td>TNX-701</td>
<td>Radioprotection</td>
<td>Preclinical</td>
</tr>
<tr>
<td><strong>Immunology &amp; Immuno-Oncology</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>TNX-1500⁸</td>
<td>Organ Transplant Rejection/ Autoimmune Conditions</td>
<td>Phase 1, Targeting 2H 2022 Start</td>
</tr>
<tr>
<td>TNX-1700⁹</td>
<td>Gastric, colorectal and pancreatic cancers</td>
<td>Preclinical</td>
</tr>
</tbody>
</table>

*All of Tonix’s product candidates are investigational new drugs or biologics and have not been approved for any indication.

¹Live attenuated vaccine based on horsepox virus vector, expressed SARS-CoV-2 spike protein.

²Pre-IND (Investigational New Drug) meeting with FDA completed; Company plans to start Phase 2 study in subset of patients whose symptoms overlap with fibromyalgia pending IND clearance.

³*in vivo* diagnostic: SARS-CoV-2 peptide epitope mixtures for intradermal administration to measure delayed-type hypersensitivity to SARS-CoV-2.

⁴Sangivamycin for injection.

⁵Humanized monoclonal antibody generated from COVID-19 convalescent patients

⁶anti-CD40L COVID vaccine based on mRNA in Zinc Nanopartical (ZNP) formulation

⁷Live attenuated vaccine based on horsepox virus

⁸anti-CD40L humanized monoclonal antibody

⁹Recombinant trefoil factor 2 (rTFF2) based protein; licensed from Columbia University
## PIPELINE

### CNS PORTFOLIO

<table>
<thead>
<tr>
<th>Candidates</th>
<th>INDICATION</th>
<th>STATUS / NEXT MILESTONE</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>CNS</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>TNX-102 SL¹</td>
<td>Fibromyalgia (FM)</td>
<td>Mid-Phase 3</td>
</tr>
<tr>
<td></td>
<td>Posttraumatic Stress Disorder (PTSD)</td>
<td>Phase 2, Targeting 1H 2022 Start</td>
</tr>
<tr>
<td></td>
<td>Long COVID (PASC²)</td>
<td>Phase 2, Targeting 1H 2022 Start³</td>
</tr>
<tr>
<td>TNX-1300⁴</td>
<td>Cocaine Intoxication / Overdose</td>
<td>Phase 2, Targeting 1Q 2022 Start</td>
</tr>
<tr>
<td>TNX-1900⁵</td>
<td>Migraine and Craniofacial Pain</td>
<td>Phase 2, Targeting 2H 2022 Start⁶</td>
</tr>
<tr>
<td>TNX-2900⁷</td>
<td>Prader-Willi Syndrome</td>
<td>Preclinical</td>
</tr>
<tr>
<td>TNX-601 CR</td>
<td>Depression, PTSD, Neurocognitive Dysfunction from Steroids</td>
<td>Phase 2, Targeting 1H 2022 Start⁸</td>
</tr>
<tr>
<td>TNX-1600⁹</td>
<td>Depression, PTSD and ADHD</td>
<td>Preclinical</td>
</tr>
</tbody>
</table>

---

*All of Tonix's product candidates are investigational new drugs or biologics and have not been approved for any indication.*

¹TNX-102 SL (cyclobenzaprine HCl sublingual tablets) is an investigational new drug and has not been approved for any indication. Long COVID/PASC program is also included in the COVID-19 Portfolio.

²Additional indications of Agitation in Alzheimer’s Disease (AAD) and Alcohol Use Disorder (AUD) are Phase 2 ready.

³Pre-IND (Investigational New Drug) meeting with the FDA completed; Company plans to file IND to support Phase 2 study in patients whose symptoms overlap with fibromyalgia.

⁴TNX-1300 (double-mutant cocaine esterase) is an investigational new biologic and has not been approved for any indication; licensed from Columbia University.

⁵Acquired from Trigemina; license agreement with Stanford University; IND cleared.

⁶A Phase 2 trial under an investigator-initiated IND has been completed in the U.S. using TNX-1900; Phase 2 expected to start 2H'22.

⁷Co-exclusive license agreement with French National Institute of Health and Medical Research (Inserm)

⁸TNX-601 CR is in the pre-IND stage in the U.S.; a Phase 1 trial for formulation development was completed outside of the U.S.; Phase 2 expected to start 1H 2022.

⁹Acquired from TRImaran Pharma; license agreement with Wayne State University.

ADHD = attention-deficit hyperactivity disorder; FM = fibromyalgia; IND = investigational new drug; PASC = post-acute sequelae of COVID-19; PTSD = posttraumatic stress disorder.
COVID-19: THE MISSING PIECES

DELTA AND OMICRON VARIANTS ARE SURGING IN THE US

• **Vaccines**: early vaccines slowed pandemic, but are showing limitations
  – Short term protection – requirement for boosters; uncertain protection against variants

• **Anti-viral drugs**: Veklury® (remdesivir), Paxlovid™ (nirmatrelvir\(^1\)), and Lagevrio® (molnupiravir) are available
  – Pfizer’s Paxlovid looks promising; Merck’s Lagevrio did not show benefit in 2\(^{nd}\) cohort\(^2\)

• **Anti-SARS-CoV-2 monoclonal antibodies**: increasing adoption
  – Concerns about monoclonals and variants: only Vir/GSK’s XEVURDY® (sotrovimab) is believed active against the omicron variant of SARS-CoV2

• **Tests**: measurement of functional T cell immunity is a new frontier

• **Long COVID**: no approved treatment for ‘Long Covid’

\(^1\)PAXLOVID™ (nirmatrelvir plus ritonavir)
COVID-19 VACCINES: WHERE WE ARE TODAY

Durability of protection
- mRNA vaccinated people lose protection, starting at 4-6 months
- Increasing rates of “breakthrough” COVID
- Booster vaccinations with mRNA vaccines at 6 months

Effect on forward transmission (spread of infection to others)
- Concerns about whether vaccinated people can be infectious to others

Detecting vaccine failure
- Need a strategy for identifying individuals at risk after vaccination

No recognized, clinical applicable biomarker of vaccine protection
- Best proxy is neutralizing antibodies, which are hard to measure

Current and future variants (e.g., Delta, Omicron variants)
- Less protection from existing vaccines
- Unknown effectiveness for future variants

¹www.cdc.gov/media/releases/2021/s0818-covid-19-booster-shots.html
mRNA vaccines have slowed pandemic, but may not be a long-term solution
- Vaccinated people lost protection, increasing rates of “breakthrough” COVID
- COVID is becoming endemic; vaccination of entire world every 6 months not practical

**Operation Warp Speed (OWS) identified 4 types of vaccines:**
1. RNA/DNA – Pfizer\(^1\) and Moderna\(^2\) are fully approved by the FDA
2. Subunit – NovaVax has good data, but manufacturing issues – not available
3. Non-replicating – J&J has EUA; AstraZeneca widely used ex-US
4. Live Virus Vaccines – none were ultimately adopted by OWS

**Live Virus Vaccines**
- Merck was developing two programs: VSV and Measles, but they were not included in OWS and were abandoned in January 2021\(^3\)

\(^1\)COMIRNATY is the brand name for the Pfizer-BioNTech COVID-19 vaccine
LIVE VIRUS VACCINES: DEVELOPMENT RATIONALE

• Control of smallpox, measles, mumps, rubella, chickenpox and other viral conditions
  – Prevent forward transmission

• Effective in eliciting durable or long-term immunity

• Economical to manufacture at scale
  – Low dose because replication amplifies dose in vivo
  – Single shot administration

• Standard cold chain required for shipping and storage

• Live virus vaccines are the oldest vaccine technology
  – Starting with Edward Jenner's smallpox vaccine, the first vaccine, eradicated smallpox
VACCINIA INDUCES A SKIN REACTION CALLED “TAKE” – DESCRIBED BY DR. EDWARD JENNER

• Biomarker of protection
  – Smallpox was eradicated using this marker
  – Revaccination indicated for recipients without “take”

• Measure of T cell immunity
  – No need for blood draws or complex laboratory studies
  – No other functional T cell assay is approved or in clinical use for vaccination

*Example of major cutaneous reaction, or “take,” resulting from a replication-competent live-virus vaccine with intradermal delivery, indicating successful vaccination1,2

LIVE VIRUS VACCINE PLATFORM:
NEW RECOMBINANT POX VACCINE (RPV) TECHNOLOGY FOR EMERGING INFECTIOUS DISEASES AND ONCOLYTICS

RPV VECTOR BELIEVED SIMILAR TO EDWARD JENNER’S VACCINE

Using Proven Science To Address Challenging Disease States, We Have Created A Programmable Technology Platform Aimed At Combating Future Threats To Public Health

2Esparza, J. Vaccine. 2020 Jun 19; 38(30): 4773-4779. doi: 10.1016/j.vaccine.2020.05.037
LIVE VIRUS RECOMBINANT POX VACCINE (RPV)  
PLATFORM PROFILE

POTENTIALLY LONGER DURABILITY DUE TO POX-ENGINEERED ARCHITECTURE
• Enables broad CD8+ T cell response, resulting in strong immune response

PROGRAMMABLE VECTOR DESIGN FOR USE IN DIFFERENT DISEASE MODELS
• Responsive to new variants
• Wide range of clinical applications: pandemic, biodefense, infectious disease, smallpox, oncology

VIRUS-BASED SCIENCE IS WELL ESTABLISHED
• Streamlined development
• Ability to vertically integrate development and manufacturing
• Multi-dose packaging, standard cold-chain products
TNX-1800*: COVID-19 VACCINE
LIVE VIRUS PLATFORM DEVELOPMENT PROGRAM

ESTABLISHES LIVE VIRUS PLATFORM
• Encodes a protein from SARS-CoV-2, the cause of COVID-19
• Provides a novel, variant-reflexive alternative to mRNA products

ANIMAL TESTING WITH SOUTHERN RESEARCH INSTITUTE
• Non-human primate immune response: positive results reported in Q4 2020
• Non-human primate CoV-2 challenge testing: positive data reported in Q1 2021

DEVELOPED IN COLLABORATION WITH UNIVERSITY OF ALBERTA AND MANUFACTURING AGREEMENT WITH FUJIFILM DIOSYNTH
• GMP clinical supply expected to be ready for human trials in 2H 2022

DEVELOPMENT PROGRAM

Market Entry: COVID-19 Vaccine
Additional Indications: Future Pandemic, Infectious Disease, Smallpox, Cancer

Status: Preclinical
Next Steps: 2H 2022 Initiate Phase 1 Study

*TNX-1800 is in the pre-IND stage of development and has not been approved for any indication.
LIVE VIRUS PLATFORM: WHAT MAKES TNX-1800 DIFFERENT FROM mRNA VACCINES

<table>
<thead>
<tr>
<th>CRITERIA</th>
<th>mRNA VACCINES</th>
<th>TNX-1800*</th>
</tr>
</thead>
<tbody>
<tr>
<td>Number of shots</td>
<td>Two</td>
<td>One</td>
</tr>
<tr>
<td>Duration</td>
<td>6 months</td>
<td>Years / decades</td>
</tr>
<tr>
<td>Boosters</td>
<td>Recommended</td>
<td>Likely not required</td>
</tr>
<tr>
<td>Protection from variants</td>
<td>Variants</td>
<td>Expected</td>
</tr>
<tr>
<td>Forward transmission</td>
<td>Unknown for variants</td>
<td>Likely prevents</td>
</tr>
<tr>
<td>Biomarker</td>
<td>None</td>
<td>Yes – “Take”</td>
</tr>
<tr>
<td>Manufacturing</td>
<td>Complex</td>
<td>Conventional</td>
</tr>
<tr>
<td>Glass-sparing packaging</td>
<td>No</td>
<td>Yes</td>
</tr>
<tr>
<td>Shipping and storage</td>
<td>Cold chain</td>
<td>Standard refrigeration</td>
</tr>
<tr>
<td>Protection from smallpox</td>
<td>No</td>
<td>Yes</td>
</tr>
</tbody>
</table>

* Characterizations of TNX-1800 show in table represent expectations.
LIVE VIRUS RPV PLATFORM & COVID-19 VACCINE
INTERNAL DEVELOPMENT & MANUFACTURING CAPABILITIES

Infectious Disease R&D Center (RDC) – Frederick, MD
• Function: Accelerated development of vaccines and antiviral drugs against COVID-19, its variants and other infectious diseases
• Description: ~48,000 square feet; currently BSL-2 but being converted to BSL-3
• Status: Operational; acquisition completed on October 1st, 2021

Advanced Development Center (ADC) – New Bedford, MA
• Function: Development and clinical scale manufacturing of live-virus vaccines to support Phase 1 and Phase 2 trials
• Description: ~45,000 square feet, under construction, planned BSL-2
• Status: Expected to be partially operational in first half 2022

Commercial Manufacturing Center (CMC) – Hamilton, MT
• Function: Phase 3 and Commercial scale manufacturing of live-virus vaccines
• Description: ~44 acre green field site, planned BSL-2
• Status: Planning for site enabling work in 2022
• “Platforms” – Foundation of Pandemic Response
  – Key element of AP3 from White House Office of Science and Technology Policy or OSTP¹,²
    ▪ 100 days to human trials
    ▪ Technologies that do not require sterile injection

• TNX-801/-1800 (live virus RPV) platform addresses OSTP requirements¹,²
  – Our goal is to be able to test new live virus vaccines against novel pathogens within the 100 days of obtaining sequence
    ▪ RDC is equipped to make new vaccines
    ▪ ADC will be equipped to make clinical trial material
    ▪ CDC is planned to make commercial scale material

TWO TYPES OF IMMUNITY

- **Antibodies** – can be measured in a blood test, but anti-SARS-CoV-2 antibodies are not predictive of protection
- **T cell** – can be measured in a blood test, but requires sophisticated lab, unknown if predictive

NEUTRALIZING ANTIBODIES – APPEAR TO CORRELATE WITH PROTECTION\(^1\)

- Not part of standard antibody tests
- Requires culture of antibodies with live SARS-CoV-2; possibly “pseudo-type” assays

FUNCTIONAL T CELL IMMUNITY

- *in vivo* – classic skin test – correlation with protection under investigation\(^2,3\)

---


\(^3\)Barrios, Y et al. Vaccines (2021) 9:575
TNX-2100*: SARS-COV-2 DIAGNOSTIC TO MEASURE T CELL IMMUNITY

**DESIGNED TO MEASURE THE PRESENCE AND STRENGTH OF FUNCTIONAL IN VIVO T CELL IMMUNITY**

- Designed to elicit delayed-type hypersensitivity in individuals who have been exposed to SARS-CoV-2 or successfully vaccinated
- SARS-CoV-2 epitope peptide mixtures for intradermal administration (Skin Test)

**POTENTIALLY SCALABLE FOR WIDESPREAD USE**

- Many tests† for T cell immunity to SARS-CoV-2 require specialized laboratories and are not amendable to standardization
- Adaptive Biotech’s T Detect™ COVID-19 test received FDA EUA based on genetic analysis of T cell receptors

*TNX-2100 has not been approved for any indication.
†Intracellular cytokine staining (ICS) measured by flow cytometry after in vitro stimulation of purified peripheral blood mononuclear cells.
TNX-2100*: POTENTIAL USES AND DEVELOPMENT PLAN

POTENTIAL BENEFITS OF TESTING FOR PROTECTIVE IMMUNITY
- Personalized approach to determine need for vaccine boosters
  - One-size-fits-all booster strategy is unsustainable
- More cost effective
- Reduces risks associated with unnecessary vaccination

DEVELOPMENT PLANS
- Initiated first-in-human, dose-finding clinical study in January 2022
- Topline data expected first half 2022
- Patents filed

*TNX-2100 has not been approved for any indication.
†Intracellular cytokine staining (ICS) measured by flow cytometry after in vitro stimulation of purified peripheral blood mononuclear cells.
SMALL MOLECULE COVID-19 THERAPEUTICS

The only COVID-19 antiviral that is FDA approved is Remdesivir/Veklury®
– Gilead – Intravenous (i.v.) medicine
– FDA approved for patients who are at least 12 years old and require hospitalization
– May shorten the time to recover from acute COVID-19
– World Health Organization has recommended against its use¹
– Resistance reported²

Anti-virals in Phase 3 available
– Pfizer – PAXLOVID™ (PF-07321332; ritonavir) - oral protease C3L inhibitor - Emergency Use Authorization (EUA)
– Merck/Ridgeback – molnupiravir, oral, - EUA³

Concerns about anti-viral efficacy
– Remdesivir resistance reported²
– Molnupiravir efficacy was not repeated in second cohort of Phase 3 trial⁴

**TNX-3500*: COVID-19 ANTIVIRAL TREATMENT**

**SANGIVAMYCIN**

**PROFILE**

New variants heighten need for therapeutics

NIH Treatment Guidelines for COVID-19 are mixed on use of remdesivir

Potential monotherapy antiviral\(^1,2\)
- 65 times more potent than remdesivir in inhibiting SARS-CoV-2 in cell culture infectivity studies (dose to achieve IC\(_{90}\))

Potential combination therapy with remdesivir\(^1,2\)
- TNX-3500 antiviral effect is additive when combined with remdesivir and reduces the amount of each drug necessary for an IC\(_{90}\)
- Combination therapies for other viruses have reduced the emergence of drug resistant viral strains

**DEVELOPMENT PROGRAM**

**Market Entry:** COVID-19 Antiviral

**Additional Indications:** MERS, Ebola, Lassa, Oncology

**Status:** Preclinical

**Next Steps:** 1H 2022 Initiate Animal Studies

MERS = Middle East Respiratory Syndrome; NIH = National Institutes of Health; PK = pharmacokinetics.

---

2. Bennett, RP et al. *JCI Insight*. 2021 in press preview 10.1172/jci.insight.153165

*TNX-3500 is in the pre-IND stage of development and has not been approved for any indication.*
MONOCLONAL ANTIBODY COVID-19 THERAPEUTICS

Monoclonal antibodies (mAbs) (EUA) – 2 with US Emergency Use Authorization¹

– Vir/GSK – XEVURDY® (sotrovimab)¹ – ONLY mAb ACTIVE AGAINST OMICRON
  ▪ Derived from a convalescent Patient
– AstraZeneca – Evusheld (Tixagevimab/cilgavimab) – EUA for long term prophylaxis

New mAbs under development²

– AstraZeneca – AZD7442 – EUA request submitted³
– Brii Biosciences – BR1I-196 and BR1I-198⁴
  ▪ Derived from a convalescent Patient
– Adagio Therapeutics – ADG20⁵
– Many other companies⁶

Concerns about efficacy of mAbs against new variants

– Regeneron/Genentech - REGEN-COV® Casirivimab/imdevimab
  ▪ EUA revised Jan ‘22 to susceptible variants – unlikely to be effective against omicron
– Eli Lilly/AbCellera – Bamlanivimab/etesevimab
  ▪ EUA revised Jan ‘22 to susceptible variants – unlikely to be against omicron
– Delta and Omicron variants have many changes in the spike protein, which is the target of current mAbs

¹Indicated for individuals with mild-to-moderate COVID-19 who are at high risk for progression to severe disease; ¹¹Dec 7, 2021

Glaxo Says Its Covid-19 Antibody Drug Works Against Omicron - WSJ


⁵https://endpts.com/qa-tillman-gerngross-explains-why-his-covid-mab-will-have-an-edge-over-an-already-crowded-field/

⁶e.g., Centivax, Corat Therapeutics, IDBiologics, Leyden Labs, Memo Therapeutics and SpikImm
**TNX-3600*: COVID-19 THERAPEUTIC FULLY HUMAN MONOCLONAL ANTIBODY PLATFORM**

**PROFILE**

Collaboration with Columbia University

Human monoclonal antibodies (mAbs) generated from COVID-19 convalescent patients

Potential monotherapies

• Plan to seek indication similar to current EUA therapeutic mAbs for treating individuals with mild-to-moderate COVID-19 who are at high risk for progression to severe disease

Potential combination therapy with other antibodies

• Combination therapies for other anti-CoV-2 monoclonal antibodies are believed to have reduced the emergence of drug resistant viral strains

**DEVELOPMENT PROGRAM**

**Market Entry:** COVID-19 Therapeutic

**Additional Indications:** Symptomatic COVID in patients with risk factors for poor outcome

**Status:** Preclinical

**Next Steps:** Study inhibition of SARS CoV-2 variants in tissue culture; 1H 2022 Initiate Animal Studies

Given the unpredictable trajectory of the SARS-CoV-2 virus and new variants\(^1\), we seek to contribute to a broad set of monoclonal antibodies from a variety of patients, that can be scaled up quickly and potentially combined with other monoclonal antibodies.

*TNX-3600 is in the pre-IND stage of development and has not been approved for any indication.

\(^1\)Waltz, E. Nature. “Does the World Need an Omicron Vaccine?” 28 Jan 2022 [https://www.nature.com/articles/d41586-022-00199-z](https://www.nature.com/articles/d41586-022-00199-z)
TNX-3700*: COVID-19 VACCINE
ZINC NANOPARTICLE (ZNP) FORMULATION FOR mRNA VACCINE

PROFILE

Collaboration with Kansas State University

ZNP technology is a potential replacement for the Lipid Nanopartical (LNP) technology of current mRNA vaccines

Potential improved stability
- Plan to seek initial indications as booster, similar to the current EUA and FDA approved mRNA vaccines
- Improved stability would facilitate shipping and storage

Addresses limitations in current mRNA vaccines which require ultra-cold storage and shipping
- Stability issues limit use in less developed countries

DEVELOPMENT PROGRAM

Market Entry: Booster for COVID-19 Vaccines

Additional Indications: COVID-19 vaccine for naïve individuals

Status: Preclinical

Next Steps: Research at K-State on CoV-2 spike based vaccine in tissue culture and animals; 1H 2022 Initiate Animal Studies

*TNX-3700 is in the pre-IND stage of development and has not been approved for any indication.

© 2022 Tonix Pharmaceuticals Holding Corp.
TNX-102 SL*: LONG COVID (PASC) CYCLOBENZAPRINE PROTECTIC® SUBLINGUAL TABLETS

PROFILE

Long COVID or Post-acute Sequelae of COVID-19 (PASC)¹

• Symptoms can include fatigue, sleep disorders, pain, fevers, shortness of breath, cognitive impairment described as “brain fog”, gastrointestinal symptoms, anxiety, and depression²
• Can persist for months and can range in severity from mild to incapacitating
• Occurs in 30% of recovered COVID-19 patients
• Typically associated with moderate or severe COVID-19, Long COVID can occur after mild COVID-19 or even after asymptomatic SARS-CoV-2 infection

To address the urgent need for PASC therapies, Congress awarded the National Institutes of Health $1.15 billion to study Long COVID.³

DEVELOPMENT PROGRAM

Market Entry: Long COVID (PASC)

Status: Clinical – pre-IND; FDA minutes from pre-IND meeting received in Q3 2021

Next Steps: Start Phase 2 study for treating subset of Long COVID patients whose symptoms overlap with fibromyalgia in 1H 2022

*TNX-102 SL is in the pre-IND stage of development for Long Covid and has not been approved for any indication.

³The NIH provision of Title III Health and Human Services, Division M--Coronavirus Response and Relief Supplemental Appropriations Act, 2021, of H.R. 133, The Consolidated Appropriations Act of 2021. The bill was enacted into law on 27 December 2020, becoming Public Law 116-260.
TNX-1500*: PREVENTION OF ALLOGRAFT REJECTION
NEXT GENERATION CD40 LIGAND (CD40L) ANTIBODY

THE CD40-CD40L PATHWAY IS A PIVOTAL IMMUNE SYSTEM MODULATOR AND IS A WELL-ESTABLISHED AND PROMISING TREATMENT TARGET TO MORE SAFELY PREVENT ALLOGRAFT REJECTION¹

First Generation: Development halted due to thromboembolic (TE) complications—blood clots—traced to Fc gamma receptor (FcγR)

Second Generation: Eliminated the FcγR TE complication but potency and half life was reduced, limiting utility

Third Generation (TNX-1500): Re-engineered to better modulate the binding of FcγR while preserving FcRn function
  • Expected to deliver efficacy without compromising safety

Status: Preclinical; collaborations ongoing with Mass General Hospital on heart and kidney transplantation in non-human primates

Next Steps: 2H 2022 Initiate Phase 1 Study

TNX-1700*: GASTRIC, COLORECTAL AND PANCREATIC CANCERS
STABILIZED RECOMBINANT TREFOIL FACTOR 2 (rTFF2)

POTENTIAL NEW CANCER TREATMENT
• TNX-1700 (rTFF2) has effects on cancer by altering the tumor micro-environment
• Mechanism of action: suppresses myeloid-derived suppressor cells and activates anti-cancer CD8+ T cells
• Potential synergy with anti-PD-1 or anti-PD-L1 monoclonal antibodies (mAbs)

PRECLINICAL EVIDENCE FOR INHIBITING GROWTH OF CANCER CELLS
• Data showed that TFF2-CTP augmented the efficacy of mAb anti-PD-1 therapy. Anti-PD-1 in combination with TFF2-CTP showed greater anti-tumor activity in PD-L1-overexpressing mice.

LICENSED FROM COLUMBIA UNIVERSITY
• Developing in partnership under sponsored research agreement

DEVELOPMENT PROGRAM

Market Entry: Gastric and colorectal

Additional Indications: Pancreatic cancers

Status: Preclinical

Next Steps: Animal studies ongoing

*TNX-1700 is in the pre-IND stage of development and has not been approved for any indication.
TNX-102 SL*: FIBROMYALGIA
Cyclobenzaprine PROTECTIC® SUBLINGUAL TABLETS

PROFILE
A unique formulation of cyclobenzaprine designed to optimize delivery and absorption
Innovative and proprietary PROTECTIC® Rapid drug exposure following nighttime administration
  • Lower daytime exposure
  • Avoids first-pass metabolism
    ▪ Reduces risk of pharmacological interference from major metabolite

Clinical trial program designed to examine treatment of core Fibromyalgia symptoms

DEVELOPMENT PROGRAM

Market Entry: Fibromyalgia

Additional Indications: PTSD, Agitation in Alzheimer’s, Alcohol Use Disorder, Long COVID

Status: One Positive Phase 3 study (RELIEF) Completed

Next Steps: Second Phase 3 Study (RALLY/F306): clinical phase completed, and topline data expected 1Q 2022. Confirmatory Phase 3 planned for 1H 2022

*TNX-102 SL has not been approved for any indication.

Patents Issued
Phase 3 Study, RALLY (F306)

- July 2021: Tonix stopped enrollment in the RALLY study following an unblinded, pre-planned interim analysis by the Independent Data Monitoring Committee (IDMC).
- Based on interim analysis results of the first 50% (n=336) enrolled participants, the IDMC recommended stopping the trial as TNX-102 SL is unlikely to demonstrate a statistically significant improvement in the primary endpoint.
- Clinical phase of study completed, with 514 participants enrolled overall – 399 completers; topline results expected 1Q 2022
- Confirmatory Phase 3 study (F307) planned 1H 2022

*Following analysis of F306 results, including pharmacogenetic comparison of F304 and F306, Tonix may modify F307 protocol*

TNX 102-SL Development Beyond Fibromyalgia

- Development efforts continue in PTSD, Agitation in Alzheimer’s, Alcohol Use Disorder, Long COVID
TNX-601 CR*: PSYCHIATRY
TIANEPTINE OXALATE AND NALOXONE

PROFILE
A novel, oral, controlled release once-daily tablet

Mechanistically different from traditional monoaminergic treatments for depression

Indirectly modulates the glutamatergic system
• No direct binding to NMDA, AMPA, or kainate receptors

Naloxone added to deter parenteral abuse

Treatment effect of tianeptine in depression is well-established

DEVELOPMENT PROGRAM

Market Entry: Major Depressive Disorder

Additional Indications: PTSD, Neurocognitive Disorder From Corticosteroids

Status: Clinical – pre-IND

Next Steps: 1H 2022 Initiate Phase 2 Trial

*TNX-601 CR is in the pre-IND stage of development and has not been approved for any indication.
TNX-1900*: MIGRAINE
INTRANASAL POTENTIATED OXYTOCIN (OT) WITH MAGNESIUM

PROFILE

Intranasal OT has potential utility in treating migraine:
- Intranasal OT reaches the trigeminal ganglion
- Preclinical evidence of OT blocking CGRP release and suppressing pain
- Association of low OT levels during and preceding migraine episodes
- Novel non-CGRP antagonist approach to treatment

Magnesium is known to potentiate the binding of OT to its receptor

One billion individuals worldwide suffer from migraines

DEVELOPMENT PROGRAM

Market Entry: Chronic Migraine

Additional Indications: Acute Migraine, Craniofacial Pain, Insulin Resistance

Status: Clinical – IND cleared

Next Steps: 2H 2022 Initiate Phase 2 Trial

---

3. A Phase 2 trial under an investigator-initiated IND has been completed in the U.S. using TNX-1900

CGRP = calcitonin gene-related peptide.

*TNX-1900 has not been approved for any indication.
TNX-2900*: PRADER-WILLI SYNDROME
INTRANASAL POTENTIATED OXYTOCIN (OT) WITH MAGNESIUM

PROFILE

Prader-Willi Syndrome is the most common genetic cause of life-threatening childhood obesity
- Orphan disease occurring in 1 in 15,000 births

Symptoms include lack of suckling as infants, poor muscle strength, and constant hunger (hyperphagia)
- In animal models, OT has improved suckling and suppressed hunger
  - Tonix’s patented potentiated OT formulation is believed to increase specificity for OT receptors relative to off-target vasopressin receptors

DEVELOPMENT PROGRAM

Market Entry: Prader-Willi Syndrome

Additional Indications: Rare, Orphan Hyperphagia Conditions

Status: pre-IND; orphan drug designation application submitted to FDA

Next Steps: Submit application to the FDA for Fast Track designation

*TNX-2900 is in the pre-IND stage of development and has not been approved for any indication.

Patents Issued
TNX-1300*: COCAINE INTOXICATION
COCAINE ESTERASE (CoCe)

PROFILE

Cocaine is the main cause for drug-related ED visits\(^1\)

Cocaine use can cause irreversible structural damage to the heart and accelerate cardiovascular disease\(^2\)
  - In one survey of 94 long-term cocaine users, 71% had some form of cardiovascular disease\(^3\)

CoCe is a recombinant protein that degrades cocaine in the bloodstream
  - Rapidly reverses physiologic effects of cocaine
  - Drops plasma exposure by 90% in 2 minutes

DEVELOPMENT PROGRAM

Market Entry: Cocaine Intoxication

Additional Indications: Cocaine Overdose

Status: Phase 2 Open Label

Next Steps: Q1 2022 Initiate Trial

FDA Breakthrough Therapy Designation

*TNX-1300 has not been approved for any indication.

ED = emergency department.


ED = emergency department.
KEY DEVELOPMENT PARTNERS

TNX-1500: ALLOGRAFT REJECTION

TNX-1900: MIGRAINE & OTHER INDICATIONS

TNX-2900: PRADER-WILLI SYNDROME

TNX-1300: COCAINE INTOXICATION
TNX-1700: GASTRIC AND PANCREATIC CANCERS
TNX-3600: MONOCLONAL ANTIBODIES FOR COVID-19 TREATMENT

TNX-1800: COVID-19 VACCINE
MILESTONES:
RECENTLY COMPLETED AND UPCOMING*

- **4th Quarter 2020**  Positive topline data from TNX-102 SL Phase 3 F304/RELIEF study in fibromyalgia reported
- **1st Quarter 2021**  Non-human primate positive efficacy data from TNX-1800 in COVID-19 models reported
- **1st Quarter 2022**  First-in-human clinical study of TNX-2100 initiated for skin test to detect T cell immunity to SARS-CoV-2

Expected Data
- **1st Quarter 2022**  Topline data from TNX-102 SL Phase 3 F306/RALLY study in fibromyalgia
- **1st Half 2022**  Topline data from first-in-human TNX-2100 skin test study

Expected Clinical Trial Initiations
- **1st Quarter 2022**  Phase 2 OL safety study start of TNX-1300 in ED setting for cocaine intoxication
- **1st Half 2022**  Phase 2 study start of TNX-102 SL for the treatment of PTSD in Kenya
- **1st Half 2022**  Phase 3 study start of TNX-102 SL for the management of fibromyalgia
- **1st Half 2022**  Phase 2 study start of TNX-102 SL for the treatment of Long COVID
- **1st Half 2022**  Phase 2 study start of TNX-601 CR for the treatment of major depressive disorder
- **2nd Half 2022**  Phase 2 study start of TNX-1900 for the treatment of migraine
- **2nd Half 2022**  Phase 1 study start of TNX-1800 for COVID-19
- **2nd Half 2022**  Phase 1 study start of TNX-1500 for prevention of allograft rejection

* We cannot predict whether the global COVID-19 pandemic will impact the timing of these milestones.
MANAGEMENT TEAM

Seth Lederman, MD
Co-Founder, CEO & Chairman

Gregory Sullivan, MD
Chief Medical Officer

Bradley Saenger, CPA
Chief Financial Officer

Jessica Morris
Chief Operating Officer
THANK YOU